ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS ATHE 深 沪
等待开盘 09-16 09:30:00 美东时间
4.638
-0.242
-4.96%
华盛通- 最 高5.00
- 今 开5.00
- 成交量 3.89万股
- 最 低 4.58
- 昨 收 4.88
- 总市值 6865.82万
- 52周最高 7.00
- 市盈率 静 --
- 换手率 0.26%
- 52周最低 1.001
- 委 比 90.48%
- 总股本 1480.34万
- 历史最高 51.50
- 量 比 3.07
- 振 幅 8.61%
- 历史最低 1.001
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
Alterity Therapeutics announced positive results from its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA). The study showed that ATH434, at 50 mg and 75 mg doses, slowed disease progression and was well tolerated. Key findings included reduced disease severity, improvement in core symptoms, and maintained function in daily activities. The drug also reduced iron accumulation in affected brain regions, indicating target engagemen...
09-15 11:25
Alterity Therapeutics’ ATH434 Shows Promise in Phase 2 MSA Trial
Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeut...
09-15 11:19
Alterity Therapeutics Issues Over 1.6 Billion New Shares
An update from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity T...
09-15 09:19
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
Alterity Therapeutics announced a successful capital raise of A$20 million to fund the development of its lead drug ATH434 for treating neurodegenerative diseases like MSA. CEO David Stamler highlighted positive Phase 2 trial results and the company’s strategic focus on advancing regulatory and clinical activities. Proceeds will strengthen Alterity’s balance sheet, support ongoing research, and facilitate potential partnerships.
09-08 11:35
Alterity Therapeutics Announces Major Securities Issue
Alterity Therapeutics ( ($AU:ATH) ) has issued an announcement. Alterity Therap...
09-08 10:07
Alterity Therapeutics Secures A$20 Million to Advance Neurodegenerative Disease Treatment
An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alte...
09-08 10:07
Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement
Alterity Therapeutics ( ($ATHE) ) just unveiled an update. On September 4, 2025...
09-04 18:57
Alterity Therapeutics to Present at the Biotech Showcase
Alterity Therapeutics, a biotech company focused on neurodegenerative disease treatments, announced that CEO David Stamler will present a corporate update at the Biotech Showcase on September 3, 2025, in Australia, and September 2, 2025, in the U.S. The presentation will highlight the company's lead asset, ATH434, and its drug discovery platform. Zoom webcast registration details and contact information for investors and media are provided. The a...
09-02 11:25
Alterity Therapeutics Files Annual Report with SEC
Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeut...
09-02 10:08
Alterity Therapeutics to Present Corporate Update at Biotech Showcase
Alterity Therapeutics ( ($AU:ATH) ) has provided an announcement. Alterity Ther...
09-01 11:27
